Insights into incretin-based therapies for treatment of diabetic dyslipidemia

被引：21

作者：

Stemmer, Kerstin ^{[1
,2
,3
,4
]}

Finan, Brian ^{[5
]}

DiMarchi, Richard D. ^{[6
]}

Tschoep, Matthias H. ^{[1
,2
,3
,7
]}

Mueller, Timo D. ^{[1
,2
,3
,8
]}

机构：

[1] Helmholtz Zentrum Munchen, Inst Diabet & Obes, Ingolstadter Landstr 1, D-85764 Neuherberg, Germany

[2] Helmholtz Zentrum Munchen, Helmholtz Diabet Ctr, Neuherberg, Germany

[3] Helmholtz Zentrum Munchen, German Ctr Diabet Res DZD, Neuherberg, Germany

[4] Univ Konstanz, Dept Biol, Constance, Germany

[5] Novo Nordisk Res Ctr Indianapolis, Indianapolis, IN 46241 USA

[6] Indiana Univ, Dept Chem, Bloomington, IN 47405 USA

[7] Tech Univ Munich, Dept Med, Div Metab Dis, Munich, Germany

[8] Karls Univ Hosp & Clin, Eberhard Inst Expt & Clin Pharmacol & Pharmacogen, Dept Pharmacol Expt Therapy & Toxicol, D-72076 Tubingen, Germany

来源：

ADVANCED DRUG DELIVERY REVIEWS | 2020年 / 159卷

基金：

欧洲研究理事会;

关键词：

Incretins; Lipoproteins; Dyslipidemia; Diabetes; Obesity; GLUCAGON-LIKE PEPTIDE-1; GASTRIC-INHIBITORY POLYPEPTIDE; DEPENDENT INSULINOTROPIC POLYPEPTIDE; LIPOPROTEIN-LIPASE ACTIVITY; LOW-DENSITY-LIPOPROTEIN; DIPEPTIDYL PEPTIDASE-4 INHIBITOR; IMPAIRED GLUCOSE-TOLERANCE; BROWN ADIPOSE-TISSUE; HIGH-FAT; RECEPTOR AGONIST;

D O I：

10.1016/j.addr.2020.05.008

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Derangements in triglyceride and cholesterol metabolism (dyslipidemia) are major risk factors for the development of cardiovascular diseases in obese and type-2 diabetic (T2D) patients. An emerging class of glucagon-like peptide-1 (GLP-1) analogues and next generation peptide dual-agonists such as GLP-1/glucagon or GLP-1/GIP could provide effective therapeutic options for T2D patients. In addition to their role in glucose and energy homeostasis, GLP-1, GIP and glucagon serve as regulators of lipid metabolism. This review summarizes the current knowledge in GLP-1, glucagon and GIP effects on lipid and lipoprotein metabolism and frames the emerging therapeutic benefits of GLP-1 analogs and GLP-1-based multiagonists as add-on treatment options for diabetes associated dyslipidemia. (C) 2020 Published by Elsevier B.V.

引用

下载

页码：34 / 53

页数：20

共 50 条

[1] Incretin-based therapies for treatment of postprandial dyslipidemia in insulin-resistant states
Farr, Sarah
Adeli, Khosrow
CURRENT OPINION IN LIPIDOLOGY, 2012, 23 (01) : 56 - 61
[2] Incretin-based therapies for obesity treatment
de Mello, Aline Haas
Pra, Morgana
Cardoso, Larissa Colonetti
Schraiber, Rosiane de Bona
Rezin, Gislaine Tezza
METABOLISM-CLINICAL AND EXPERIMENTAL, 2015, 64 (09): : 967 - 981
[3] Incretin-Based Therapies
Neumiller, Joshua J.
MEDICAL CLINICS OF NORTH AMERICA, 2015, 99 (01) : 107 - +
[4] Effects of Incretin-Based Therapies on Diabetic Microvascular Complications
Kang, Yu Mi
Jung, Chang Hee
ENDOCRINOLOGY AND METABOLISM, 2017, 32 (03) : 316 - 325
[5] Incretin-based therapies
Gallwitz, B.
DIABETOLOGE, 2013, 9 (04): : 283 - +
[6] Incretin-based therapies
Stonehouse, Anthony H.
Darsow, Tamara
Maggs, David G.
JOURNAL OF DIABETES, 2012, 4 (01) : 55 - 67
[7] Pancreatitis in incretin-based therapies
Famularo, Giuseppe
Morviducci, Lelio
Gasbarrone, Laura
CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY, 2015, 39 (03) : E37 - E38
[8] Incretin-based investigational therapies for the treatment of MASLD/MASH
Brouwers, Bram
Rao, Girish
Tang, Yuanyuan
Rodriguez, Angel
Glass, Leonard C.
Hartman, Mark L.
DIABETES RESEARCH AND CLINICAL PRACTICE, 2024, 211
[9] Treatment of type 2 diabetes with incretin-based therapies
Madsbad, Sten
LANCET, 2009, 373 (9662): : 438 - 439
[10] Incretin-based therapies for liver disease
Kotsiliti, Eleni
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2024, 21 (08) : 533 - 533

← 1 2 3 4 5 →